Abnormal Extracellular Vesicles and Particles from Human Islets Impact T1D progression

来自人类胰岛的异常细胞外囊泡和颗粒影响 T1D 进展

基本信息

  • 批准号:
    10754074
  • 负责人:
  • 金额:
    $ 72.91万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-08-21 至 2028-06-30
  • 项目状态:
    未结题

项目摘要

Abstract. Extracellular vesicles and particles (EVPs) are a group of heterogeneous nanoparticles that are secreted into the extracellular milieu by many types of cells. EVPs have emerged as important mediators in cell-to-cell communications within organs. Recent studies have suggested that EVPs might be involved in β cell-immune cell interaction and β cell dysfunction and survival in type 1 diabetes (T1D). However, many of these studies were performed using mouse models and not focused on human samples. Hence, there is a unmet need to understand the contribution of human islet/pancreas-associated EVPs in T1D progression. Here, we have assembled an interdisciplinary team, including experts in islet biology (Chen, Liu), EVP biology (Lyden), vascular biology (Rafii), and T1D patient care (Antal), to test the hypothesis that abnormal EVPs of pathogenic human islets and pancreatic tissues disrupt human islet function and survival and trigger T1D progression. We have performed extensive proteomics analyses of EVPs derived from human β cell lines cultured in T1D conditions. In addition, by comparing the plasma membrane protein profiles of human β cell line and primary human islet-derived EVPs with an EVP proteomic database containing 426 human samples, we have identified several plasma membrane protein candidates to isolate β cell-specific EVPs. Here, we will use multiple platforms, including primary human islets from healthy, pre-T1D, and T1D donors, human pluripotent stem cell (hPSC)-derived islet organoids, perfusable microfluidic devices containing vascularized islets, and pancreatic slice culture to systematically examine the role of human islet/pancreas-associated EVPs in islet cell function and survival during T1D progression. In this proposal, we expect to identify membrane-bound EVP protein panels to purify EVPs from human α, β cells, islets, and pancreatic tissue. We will define the EVP protein and RNA profiles and identify signature molecules associated with islet status during T1D progression. Moreover, we will systemically dissect the roles of human islet/pancreas EVPs in human β cell function and survival, as well as their role in the crosstalk between β cells and peri-islet cell niche. Overall, this study will facilitate the identification of novel “biomarkers” for T1D diagnosis and guide the development of new therapeutic strategies to treat and prevent the progression of T1D.
摘要。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Shuibing Chen其他文献

Shuibing Chen的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Shuibing Chen', 18)}}的其他基金

Decode the Impact of SARS-CoV-2 on Human Pancreas
解读 SARS-CoV-2 对人类胰腺的影响
  • 批准号:
    10319780
  • 财政年份:
    2021
  • 资助金额:
    $ 72.91万
  • 项目类别:
Decode the Impact of SARS-CoV-2 on Human Pancreas
解读 SARS-CoV-2 对人类胰腺的影响
  • 批准号:
    10646228
  • 财政年份:
    2021
  • 资助金额:
    $ 72.91万
  • 项目类别:
Decode the Impact of SARS-CoV-2 on Human Pancreas
解读 SARS-CoV-2 对人类胰腺的影响
  • 批准号:
    10443871
  • 财政年份:
    2021
  • 资助金额:
    $ 72.91万
  • 项目类别:
A High Content Chemical Screen to Identify the Drug Candidates Promoting Human Beta Cell Proliferation
用于鉴定促进人类β细胞增殖的候选药物的高内涵化学筛选
  • 批准号:
    10343755
  • 财政年份:
    2020
  • 资助金额:
    $ 72.91万
  • 项目类别:
A High Content Chemical Screen to Identify the Drug Candidates Promoting Human Beta Cell Proliferation
用于鉴定促进人类β细胞增殖的候选药物的高内涵化学筛选
  • 批准号:
    10571823
  • 财政年份:
    2020
  • 资助金额:
    $ 72.91万
  • 项目类别:
A High Content Chemical Screen to Identify the Drug Candidates Promoting Human Beta Cell Proliferation
用于鉴定促进人类β细胞增殖的候选药物的高内涵化学筛选
  • 批准号:
    10117247
  • 财政年份:
    2020
  • 资助金额:
    $ 72.91万
  • 项目类别:
Determining the Intrinsic and Environmental Signal Contributing to Early T1D Progression
确定导致早期 T1D 进展的内在信号和环境信号
  • 批准号:
    10262967
  • 财政年份:
    2020
  • 资助金额:
    $ 72.91万
  • 项目类别:
Determining the Intrinsic and Environmental Signal Contributing to Early T1D Progression
确定导致早期 T1D 进展的内在信号和环境信号
  • 批准号:
    10440517
  • 财政年份:
    2020
  • 资助金额:
    $ 72.91万
  • 项目类别:
Determining the Intrinsic and Environmental Signal Contributing to Early T1D Progression
确定导致早期 T1D 进展的内在信号和环境信号
  • 批准号:
    10157473
  • 财政年份:
    2020
  • 资助金额:
    $ 72.91万
  • 项目类别:
Determining the Intrinsic and Environmental Signal Contributing to Early T1D Progression
确定导致早期 T1D 进展的内在信号和环境信号
  • 批准号:
    10653103
  • 财政年份:
    2020
  • 资助金额:
    $ 72.91万
  • 项目类别:

相似海外基金

Defining MHC class I restricted antigen presentation to CD8 T cells in experimental AD and Tauopathy - Supplement
定义实验性 AD 和 Tau 病中 MHC I 类限制性抗原呈递至 CD8 T 细胞 - 补充
  • 批准号:
    10836880
  • 财政年份:
    2023
  • 资助金额:
    $ 72.91万
  • 项目类别:
Targeting MAL2-mediated endocytosis to enhance tumor cell antigen presentation
靶向 MAL2 介导的内吞作用以增强肿瘤细胞抗原呈递
  • 批准号:
    10734324
  • 财政年份:
    2023
  • 资助金额:
    $ 72.91万
  • 项目类别:
Antigen presentation to the adaptive immune system in the choroid contributes to ocular autoimmune disease
脉络膜中的适应性免疫系统的抗原呈递导致眼部自身免疫性疾病
  • 批准号:
    10740465
  • 财政年份:
    2023
  • 资助金额:
    $ 72.91万
  • 项目类别:
Investigation of Target Protein Degradation and Its Effect on Enhancing Cancer-Specific Antigen Presentation by Quantitative Mass Spectrometry
通过定量质谱研究靶蛋白降解及其对增强癌症特异性抗原呈递的影响
  • 批准号:
    23K04971
  • 财政年份:
    2023
  • 资助金额:
    $ 72.91万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Promoting cancer cells' antigen presentation for serving as better targets for T cell immunotherapy
促进癌细胞的抗原呈递,作为 T 细胞免疫治疗的更好靶点
  • 批准号:
    2885451
  • 财政年份:
    2023
  • 资助金额:
    $ 72.91万
  • 项目类别:
    Studentship
Targeting immunoproteasome-mediated antigen presentation in colorectal cancer immunotherapy
结直肠癌免疫治疗中靶向免疫蛋白酶体介导的抗原呈递
  • 批准号:
    10385926
  • 财政年份:
    2022
  • 资助金额:
    $ 72.91万
  • 项目类别:
Lipid Antigen Presentation as a Driver of T2D Inflammation
脂质抗原呈递作为 T2D 炎症的驱动因素
  • 批准号:
    10509043
  • 财政年份:
    2022
  • 资助金额:
    $ 72.91万
  • 项目类别:
Enhancing antigen presentation in triple negative breast cancers through CD40 agonist, Flt3 ligand, and anthracycline chemotherapy
通过 CD40 激动剂、Flt3 配体和蒽环类化疗增强三阴性乳腺癌的抗原呈递
  • 批准号:
    10704008
  • 财政年份:
    2022
  • 资助金额:
    $ 72.91万
  • 项目类别:
Sex Differences in lipid antigen presentation, impact of lipid antigen presentation on peripheral lipid metabolism
脂质抗原呈递的性别差异,脂质抗原呈递对外周脂质代谢的影响
  • 批准号:
    10818273
  • 财政年份:
    2022
  • 资助金额:
    $ 72.91万
  • 项目类别:
Enhancing antigen presentation in triple negative breast cancers through CD40 agonist, Flt3 ligand, and anthracycline chemotherapy
通过 CD40 激动剂、Flt3 配体和蒽环类化疗增强三阴性乳腺癌的抗原呈递
  • 批准号:
    10349397
  • 财政年份:
    2022
  • 资助金额:
    $ 72.91万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了